BPH management: New paradigms, new approaches

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

FDA new drug application filing expected by the end of 2021.

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.